---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence. Covers EMERGE, MaGic, and DNTH103-AU-001. 182 evidence topics quoted from 37 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 EMERGE

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.1-2"></a>

###### Trial aim stated in the company announcement of initiation

> “EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2026-06-29”
> “Primary Completion (Estimated) 2028-12”
> “Study Completion (Estimated) 2031-09”
> “First Posted 2026-06-15”
> “Last Update Posted 2026-10-30”
> “Recruiting”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 12 locations”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.2-3"></a>

###### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Pasadena, California, United States, 91106”; “Boca Raton, Florida, United States, 33432”; “Fayetteville, North Carolina, United States, 28304”; “Houston, Texas, United States, 77009” |
| Georgia | “Kutaisi, Georgia”; “Tbilisi, Georgia” |
| Ukraine | “Dnipro, Ukraine”; “Vinnytsia, Ukraine” |

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.2-4"></a>

###### Initiation announced by the company in June 2026

> “NEW YORK and WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced initiation of the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis (gMG).”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

<a id="topic-3.1.1.2-5"></a>

###### Expected timing of top-line results in the third-quarter 2026 filing

> “In June 2026, we announced the initiation of the Phase 3 registrational EMERGE trial of claseprubart in gMG. We expect to report top-line results from this trial in the second half of 2028.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-3.1.1.2-6"></a>

###### Expected timing of top-line results in the third-quarter 2026 results announcement

> “Phase 3 EMERGE trial on track with top-line results expected in 2H’28: A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL S.C. Q2W and 300mg/2mL S.C. Q4W in gMG patients was initiated in June, with top-line results expected in 2H’28.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-3.1.1.2-7"></a>

###### Planned update of top-line guidance in the November 2026 corporate deck

> “Claseprubart Updated Ph. 3 EMERGE top-line guidance (YE’27)”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.2-8"></a>

###### Member states and estimated dates in the EU trial record

> “Locations Austria, Bulgaria, Czechia, Denmark, France, Germany, Italy, Latvia, Portugal, Spain, Poland”
> “Estimated recruitment start date in EU/EEA: 10/01/2027”
> “Estimated end of trial date in EU/EEA: 26/07/2031”
> “Estimated global end date of the trial: 24/01/2032”

Source: [EU Clinical Trials Information System 2026-525298-38-00](https://euclinicaltrials.eu/ctis-public/view/2026-525298-38-00)

<a id="topic-3.1.1.2-9"></a>

###### Status and decision date by member state in the EU trial record

> “Denmark Authorised, recruitment pending 28/09/2026”
> “France Authorised, recruitment pending 28/09/2026”
> “Latvia Authorised, recruitment pending 28/09/2026”
> “Portugal Authorised, recruitment pending 29/09/2026”
> “Czech Republic Authorised, recruitment pending 29/09/2026”
> “Bulgaria Authorised, recruitment pending 29/09/2026”
> “Germany Authorised, recruitment pending 30/09/2026”
> “Poland Authorised, recruitment pending 01/10/2026”
> “Italy Authorised, recruitment pending 01/10/2026”
> “Spain Authorised, recruitment pending 02/10/2026”
> “Austria Authorised, recruitment pending 05/10/2026”

Source: [EU Clinical Trials Information System 2026-525298-38-00](https://euclinicaltrials.eu/ctis-public/view/2026-525298-38-00)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients With Generalized Myasthenia Gravis (EMERGE)”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.3-2"></a>

###### Study periods in the ClinicalTrials.gov detailed description

> “The study includes the following periods: Screening (up to 12 weeks) Randomized, blinded, controlled treatment (RCT) period (17 weeks) Extended treatment period (ETP) (104 weeks) (optional) for eligible participants [includes blinded extension period (BEP) and open-label extension (OLE) period] Safety Follow-Up period (40 weeks)”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.3-3"></a>

###### Allocation, model, and masking in the ClinicalTrials.gov record

> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Quadruple”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.3-4"></a>

###### Design described by the company at initiation

> “EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial in approximately 195 participants with generalized Myasthenia Gravis who are acetylcholine receptor antibody positive (AChR+).”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

<a id="topic-3.1.1.3-5"></a>

###### Design summary in the November 2026 corporate deck

> “EMERGE is a global Ph. 3 trial evaluating Q4W and Q2W S.C. claseprubart in AChR+ gMG; top-line data 2H’28”
> “Design: Male and female subjects randomized to receive either claseprubart or placebo for 17 weeks”
> “No ANA screening exclusion criteria or routine ANA testing during RCT or OLE, inclusion criteria of MG-ADL of ≥6 and QMG of ≥10, and 17-week S.C. treatment period per alignment with FDA”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.3-6"></a>

###### End-of-phase 2 meeting with FDA before the phase 3 trial

> “Following the successful completion of our end-of-Phase 2 meeting with the FDA in the first quarter of 2026, a Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W S.C. and 300mg/2mL Q4W S.C. in gMG patients is on track to initiate in mid-2026, with top-line results expected in 2H’28.”

Source: [Dianthus Therapeutics (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm)

> “In September 2025, we reported positive top-line results from the Phase 2 MaGic trial of claseprubart for patients with gMG and subsequently held an end-of-Phase 2 meeting with the FDA in the first quarter of 2026.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion criteria in the ClinicalTrials.gov record

> “Weight range between 40-130 kg at Screening”
> “Acetylcholine receptor antibody (AChR Ab) positive”
> “i. History of abnormal neuromuscular transmission test; ii. History of positive anticholinesterase test; iii. Clinical response to acetylcholinesterase inhibitors.”
> “Myasthenia Gravis Foundation of America (MGFA) Class II-IVa”
> “MG-ADL scale score of 6 or more”
> “QMG scale score of 10 or more”
> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and based on vaccine availability”
> “Ages Eligible for Study 18 Years to 80 Years”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.4-2"></a>

###### Key exclusion criteria in the ClinicalTrials.gov record

> “Known complement deficiency”
> “Prior history (at any time) of N. meningitidis infection”
> “Previous treatment with claseprubart (DNTH103) or participation in a clinical trial with claseprubart.”
> “Any thymic surgery/biopsy within 1 year of Screening”
> “Any known or untreated thymoma.”
> “Rituximab or other B-cell targeting therapies (ie, inebilizumab) within 6 months (180 days) prior to randomization (Day 1)”
> “Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1)”
> “Diagnosis of systemic lupus erythematosus (SLE) or family history (defined as a parent, sibling, or child) of SLE”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.4-3"></a>

###### Inclusion criteria in the November 2026 corporate deck

> “Inclusion: ≥18 years old with AChR antibody + gMG, MG-ADL of ≥6 and QMG of ≥10”
> “No ANA screening exclusion criteria or routine ANA testing during the RCT or OLE”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.4-4"></a>

###### Company rationale for the QMG screening criterion

> “Adding QMG screening criteria in Ph. 3, similar to zilucoplan Ph. 3”
> “may better control for placebo response”
> “Ph. 2 study did not include QMG inclusion criteria, similar to ravulizumab Ph. 3; post-hoc analysis of MaGic data demonstrates potentially best-in-class MG-ADL improvement in patients with QMG ≥10”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.4-5"></a>

###### Removal of antinuclear antibody screening after FDA written feedback

> “Removal of anti-nuclear antibodies ("ANAs") as a screening criteria, a common reason for screen failure across all three claseprubart programs”
> “In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials.”

Source: [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Intervention described in the record |
| --- | --- |
| Claseprubart every 2 weeks | “IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart Q2W starting at Week 1 (Day 8).” |
| Claseprubart every 4 weeks | “IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart or Placebo Q2W starting at Week 1 (Day 8), with doses alternating between claseprubart and placebo.” |
| Placebo | “Intravenous (IV) infusion of Placebo on Day 1 followed by subcutaneous (SC) injections of Placebo every 2 weeks (Q2W) starting at Week 1 (Day 8).” |
| Subcutaneous product | “Prefilled syringe containing claseprubart for SC administration” |

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.5-2"></a>

###### Dose and route stated by the company

> “Following an initial loading dose, claseprubart 300mg/2mL will be administered every two or four weeks (Q2W or Q4W) via subcutaneous (S.C.) injection.”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

> “Dosing: I.V. Loading Dose followed by 300mg/2mL S.C. Q2W or Q4W starting Day 7”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.5-3"></a>

###### Rationale for the every-4-weeks regimen from the phase 2 open-label extension

> “OLE data support addition of 300mg/2mL Q4W in Ph. 3”
> “PK of ~65 μg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 μg/mL”
> “Robust reductions in MG-ADL and QMG are achieved by week 4, after just two 600mg/4mL doses and remain stable in subsequent weeks”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Data from the OLE demonstrate that after two doses of claseprubart 600mg Q2W, participants experienced robust reductions in MG-ADL and QMG at PK levels far below the steady state of the 300mg Q2W dose, supporting the potential for dosing of 300mg claseprubart every four weeks”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using MG-ADL as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary outcome measure in the ClinicalTrials.gov record

> “Change from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score”
> “Baseline (Day 1) to Week 17”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.6.1-2"></a>

###### Secondary outcome measures in the ClinicalTrials.gov record

> “Change from Baseline to Week 17 in Quantitative Myasthenia Gravis (QMG) Scale Score”
> “Change from Baseline to Week 17 in Myasthenia Gravis Composite (MGC) Scale Score”
> “Proportion of Participants with Greater Than or Equal to (≥) a 5-point Reduction in MG-ADL Scale Score at Week 17 Compared to Baseline”
> “Proportion of Participants Who Reach Minimal Symptom Expression (MSE), Defined as MG-ADL 0 or 1 at Week 17, Without Use of Rescue Therapy”
> “Proportion of Participants with a ≥ 5-point Reduction in QMG Scale Score at Week 17 Compared to Baseline”
> “Number of participants with TEAEs and treatment-emergent SAEs will be reported.”
> “Serum Concentrations of Claseprubart”
> “Change from Baseline in Complement Total Blood Test (CH50) in Serum ex vivo”
> “Incidence of Antidrug Antibody (ADAs) Against Claseprubart in the RCT Period, BEP, OLE, and Safety Follow-Up”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.6.1-3"></a>

###### Primary and secondary endpoints stated by the company

> “The primary endpoint of this trial is the change from baseline in the MG-ADL in the treatment arms versus the placebo arm. A similar evaluation is used for secondary efficacy endpoints, such as the QMG scale, MSE, MGC score and the MG-QoL-15r.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Primary: MG-ADL change from baseline”
> “Secondary / Exploratory: Efficacy (QMG, MSE, MGC, MG-QoL-15r)”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.6.1-4"></a>

###### MG-ADL scale described in the ClinicalTrials.gov record

> “The MG-ADL score is an 8-item patient reported outcome (PRO) instrument. The MG-ADL targets symptoms of disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of the MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability.”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.6.1-5"></a>

###### Validity, reliability, and use of the MG-ADL as a primary endpoint

> “Studies indicated that the MG‐ADL is a reliable and valid measure that has been used as an outcome in clinical trials and observational studies to measure MG symptoms and response to treatment. While most often used as a secondary endpoint in clinical trials, its use as a primary endpoint has increased in recent years.”
> “Since trial completion and publication of results for the phase 3 trial of eculizumab, the use of the MG‐ADL as a primary endpoint in trials has become widespread. Of trials beginning in 2018 or later, 46.7% (n = 7) have used the MG‐ADL as a primary outcome compared to 10.0% (n = 2) of trials prior to 2018”
> “The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-3.1.1.6.1-6"></a>

###### Minimal clinically important difference: 2-point improvement in the validation study

> “Correlation of the delta MG-ADL score and physician impression of change between the visits was strong (r = 0.70, P < 0.0001). A 2-point improvement in the MG-ADL best predicted clinical improvement.”
> “The MG-ADL correlates strongly with newer, validated MG outcome measures. A 2-point improvement in the MG-ADL indicates clinical improvement.”

Source: [Muppidi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22006686/)

<a id="topic-3.1.1.6.1-7"></a>

###### Minimal clinically important difference: sensitivity and specificity of each threshold

> “In this study, results from sensitivity and specificity analyses indicated that a 1‐point change in MG‐ADL was highly sensitive (96%) but did not have good specificity (71%), and a 3‐point change had good specificity (90%) but was not very sensitive (62%). A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.”
> “Of these 13 studies, 53.8% (n = 7) used a 2‐point improvement only, 30.8% (n = 4) used a 3‐point improvement only”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-3.1.1.6.1-8"></a>

###### Primary endpoint in the pivotal trial of eculizumab

> “The primary efficacy endpoint for Study ECU-MG-301 was a comparison of the change from baseline between treatment groups in the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL) total score at Week 26.”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

<a id="topic-3.1.1.6.1-9"></a>

###### Primary endpoint in the pivotal trial of ravulizumab

> “The primary efficacy endpoint was a comparison of the change from baseline between treatment groups in the MG-ADL total score at Week 26.”

Source: [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)

<a id="topic-3.1.1.6.1-10"></a>

###### Primary endpoint in the pivotal trial of zilucoplan

> “The primary efficacy endpoint was a comparison of the change from baseline between treatment groups in the Myasthenia Gravis-Specific Activities of Daily Living scale (MG- ADL) total score after twelve weeks of treatment.”

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

<a id="topic-3.1.1.6.1-11"></a>

###### Primary endpoints in the pivotal trials of efgartigimod alfa

> “In this study, an MG- ADL responder was defined as a patient with a 2-point or greater reduction in the total MG-ADL score compared to the treatment cycle baseline for at least 4 consecutive weeks, with the first reduction occurring no later than 1 week after the last infusion of the cycle.”
> “The primary efficacy endpoint was the comparison of the percentage of MG-ADL responders during the first treatment cycle between treatment groups in the anti-AChR antibody positive population.”
> “The primary efficacy endpoint was the comparison of the mean change from baseline at Week 4 between treatment groups in the MG-ADL total score.”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-3.1.1.6.1-12"></a>

###### Primary endpoint in the pivotal trial of rozanolixizumab

> “The primary efficacy endpoint was the comparison of the change from baseline between treatment groups in the MG-ADL total score at day 43.”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-3.1.1.6.1-13"></a>

###### Primary endpoint in the pivotal trial of nipocalimab

> “The primary efficacy endpoint was the comparison of the mean change from baseline to Weeks 22, 23, and 24 between treatment groups in the MG-ADL total score.”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-3.1.1.6.1-14"></a>

###### Company target for the MG-ADL treatment difference

> “Targeting >2-point MG-ADL improvement vs. placebo”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.6.1-15"></a>

###### Secondary endpoints: QMG and MGC scales described in the ClinicalTrials.gov record

> “The QMG is a clinician-reported assessment to evaluate muscle strength. The QMG consists of 13 items that measure endurance or fatiguability, with each item having a possible score that ranges from 0 - 3. The total possible QMG scores range from 0 - 39, with a higher score indicating greater disease burden.”
> “The MGC is a validated assessment tool for measuring clinical status of participants with MG. The range of total MGC score is 0 to 50, with higher scores indicating more severe disease. A clinically meaningful improvement is reflected by a 3-point improvement in MGC score.”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 195”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment stated by the company

> “The EMERGE trial is a global, randomized, multicenter, placebo-controlled Phase 3 trial of claseprubart in approximately 195 AChR+ participants with gMG.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-3.1.1.7.1-3"></a>

###### Planned participants per arm in the November 2026 corporate deck

| Arm | Planned participants |
| --- | --- |
| Claseprubart every 2 weeks | “300mg/2mL S.C. Q2W (N=65)” |
| Claseprubart every 4 weeks | “Claseprubart 300mg/2mL S.C. Q4W (N=65)” |
| Placebo | “Placebo (N=65)” |

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

EMERGE began on 2026-06-29 and has reported no efficacy or safety results; the company expects top-line results in the second half of 2028, and a company presentation lists updated EMERGE top-line guidance by the end of 2027. Enrollment is limited to approximately 195 adults aged 18 to 80 years who are acetylcholine receptor antibody positive, with an MG-ADL score of 6 or more and a QMG score of 10 or more, so participants with anti-MuSK, anti-LRP4, or seronegative generalized myasthenia gravis are not represented. The randomized, placebo-controlled period lasts 17 weeks, and longer-term data will come from an optional 104-week extended treatment period that includes an open-label extension.

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510); [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-3.1.2"></a>

#### 3.1.2 MaGic

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.1-2"></a>

###### Objective of the randomized controlled period

> “To assess the safety and efficacy of subcutaneous claseprubart in patients with AChR Ab+ gMG.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.1-3"></a>

###### Objective of the top-line results abstract

> “To assess the safety and efficacy of claseprubart in adults with acetylcholine receptor antibody positive (AChR Ab+) generalized Myasthenia Gravis (gMG).”
> “The MaGic study is the first study investigating the therapeutic potential of aC1s inhibitor in gMG.”

Source: [Peric et al. (2026b)](https://www.aan.com/msa/Public/Events/AbstractDetails/61545)

<a id="topic-3.1.2.1-4"></a>

###### Objective of the open-label extension analysis

> “Here, we report results from the ongoing MaGic study open-label extension.”
> “The primary assessment of the OLE is to evaluate the safety and tolerability of claseprubart.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.1-5"></a>

###### Objective of the minimal symptom expression analysis

> “To assess achievement of MSE in SC Q2W claseprubart-treated gMG patients in the MaGic study versus placebo.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Recruitment status | “Active, not recruiting” |
| Study start (actual) | “2024-02-23” |
| Primary completion (actual) | “2025-07-28” |
| Study completion (estimated) | “2028-10” |
| First posted | “2024-02-28” |
| Last update posted | “2026-07-27” |

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.2-2"></a>

###### Number of locations and trial identifiers in the ClinicalTrials.gov record

> “This study has 56 locations”
> “DNTH103-MG-201 2024-512865-15-00 ( EU Trial (CTIS) Number )”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.2-3"></a>

###### Trial initiation after FDA clearance of the investigational new drug application

> “February 26, 2024 at 7:00 AM EST”
> “today announced the initiation of the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis”
> “The initiation follows U.S. Food and Drug Administration (FDA) clearance of the Phase 2 Investigational New Drug (IND) application for DNTH103.”

Source: [Dianthus Therapeutics (2024a)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-2-magic-trial)

<a id="topic-3.1.2.2-4"></a>

###### Global multicenter conduct

> “MaGic is a global, multicenter, randomized, double-blind, placebo- controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SC claseprubart (NCT06282159).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.2-5"></a>

###### Top-line results reported in September 2025

> “today announced positive top-line data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart (DNTH103) in adults with acetylcholine receptor antibody positive (AChR+) generalized Myasthenia Gravis (gMG).”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.3-2"></a>

###### Study periods in the ClinicalTrials.gov record

> “Screening (up to 10 weeks)”
> “Randomized, blinded, controlled treatment (RCT) period (13 weeks)”
> “Open-label extension (OLE) period (optional) for eligible participants (104 weeks)”
> “Safety follow-up (SFU) (40 weeks)”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.3-3"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.3-4"></a>

###### Randomization 1:1:1 to two claseprubart doses or placebo for 13 weeks

> “Patients with AChR Ab+ gMG were enrolled and randomized 1:1:1 to receive claseprubart 300mg (Q2W), claseprubart 600mg (Q2W), or placebo for 13 weeks, followed by an ongoing 52-week open-label extension and 40-week safety follow-up (Figure 2).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.3-5"></a>

###### Design described at the release of top-line results

> “The MaGic trial is a global, randomized, double-blind, placebo-controlled Phase 2 trial that enrolled 65 AChR+ participants with gMG.”
> “The initial randomized treatment duration was 13 weeks, followed by a 52-week open-label extension.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.3-6"></a>

###### Design planned at trial initiation

> “The MaGic trial is a global, randomized, double-blind, placebo-controlled Phase 2 study in up to 60 patients with generalized Myasthenia Gravis who are acetylcholine receptor (AchR) antibody positive.”
> “The S.C. treatment duration will initially be 12 weeks with a 52-week open label extension.”

Source: [Dianthus Therapeutics (2024a)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-2-magic-trial)

<a id="topic-3.1.2.3-7"></a>

###### Open-label extension entry, dosing, and follow-up of participants who declined

> “OLE-eligible patients must have completed the RCT without missing >1 dose. All patients entering the OLE received claseprubart 600mg Q2W for varying periods of time before the OLE dose was unified to 300mg Q2W following RCT analysis. Patients were assessed for safety and efficacy for up to 52 weeks. Patients who declined participation in the OLE were monitored for 40 weeks after the last study dose.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Study population summarized in the poster

> “Adults aged 18–75 years (inclusive) with a diagnosis of AChR Ab+ gMG, Myasthenia Gravis Foundation of American (MGFA) Class II-IVa at screening and randomization, and Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥6 at screening and randomization were eligible to participate in this study.”
> “Individuals with current or prior use of a complement inhibitor, use of an anti-FcRn agent within 90 days of randomization, use of rituximab within 6 months, or IVIg/PLEX within 4 weeks of randomization, or any known/ untreated thymoma were not permitted to participate in the study.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.4-2"></a>

###### Inclusion criteria: age, weight, diagnosis, disease class, and MG-ADL score

> “Adult males and females, 18 to 75 years of age (inclusive) at Screening.”
> “Weight range between 40-120 kg at Screening.”
> “Diagnosis of gMG by the following tests: Acetylcholine receptor antibody (AChR Ab) positive, and One of the following: i. History of abnormal neuromuscular transmission test; ii. History of positive anticholinesterase test; iii. Clinical response to acetylcholinesterase inhibitors.”
> “Myasthenia Gravis Foundation of America (MGFA) Class II-Iva”
> “Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or more”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.4-3"></a>

###### Inclusion criterion: meningococcal vaccination

> “Vaccination against N. meningitidis with the quadrivalent meningococcal vaccine, and where available, meningococcal serotype B vaccine within 3 years prior to, or at the time of, initiating study drug.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.4-4"></a>

###### Exclusion criteria: infection history, viral infections, and thymic disease

> “Prior history (at any time) of N. meningitidis infection.”
> “Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies during Screening.”
> “Any thymic surgery/biopsy within 1 year of Screening.”
> “Any known or untreated thymoma.”
> “Any history of thymic carcinoma or thymic malignancy.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.4-5"></a>

###### Exclusion criteria: prior and concomitant therapy

> “Rituximab within 6 months (180 days) prior to randomization (Day 1)”
> “Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1).”
> “Participation in another clinical study of an investigational drug within 90 days or 5 half-lives of the investigational agent.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.4-6"></a>

###### Exclusion criterion: antinuclear antibody titer

> “An ANA titer of ≥1:320 was an exclusion criterion for the clinical trial protocol.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.4-7"></a>

###### Exclusion of prior C5 complement inhibitor use

> “Prior use of C5 complement inhibitors was exclusionary.”

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Day 1 | Week 1 to week 11 |
| --- | --- | --- |
| Placebo comparator: placebo | “Day 1: IV infusion of placebo” | “Week 1 to Week 11: placebo administered SC every 2 weeks” |
| Experimental: claseprubart 300 mg Q2W | “Day 1: IV loading dose” | “Week 1 to Week 11: Claseprubart administered SC every 2 weeks” |
| Experimental: claseprubart 600 mg Q2W | “Day 1: IV loading dose” | “Week 1 to Week 11: Claseprubart administered SC every 2 weeks” |

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.5-2"></a>

###### Intravenous loading dose followed by subcutaneous dosing every 2 weeks

> “Dosing: 15 or 20mg/kg I.V. Loading Dose followed by 300mg or 600mg S.C. Q2W starting Day 7”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.5-3"></a>

###### Loading dose by arm and subcutaneous volume

> “15 mg/kg for 300mg arm and 20 mg/kg for 600mg arm.”
> “Dosing: IV Loading Dose”
> “followed by 300mg/2mL or 600mg/4mL SC Q2W starting Day 7”

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.5-4"></a>

###### Treatment described at the release of top-line results

> “Following an initial loading dose, claseprubart was administered every two weeks (Q2W) via subcutaneous (S.C.) injection at a dose of 300mg/2mL or 600mg/4mL.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.5-5"></a>

###### Open-label extension dosing for participants switching from placebo

> “Placebo patients switching over to OLE receive 600mg Q2W with no loading dose”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.5-6"></a>

###### Open-label extension dose unified to 300 mg every 2 weeks

> “Patients eligible for the 52-week OLE were switched to, or continued, Q2W 300 mg claseprubart.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Registered primary outcome measure: treatment-emergent adverse events and serious adverse events to week 13

> “Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) Number of participants with TEAEs and treatment-emergent SAEs will be reported. Baseline (Day 1) to Week 13”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-2"></a>

###### Safety and tolerability as the primary endpoint

> “The primary endpoint of the study is safety and tolerability. Secondary endpoints include Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) and Quantitative Myasthenia Gravis (QMG) score assessments.”

Source: [Dianthus Therapeutics (2024a)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-2-magic-trial)

<a id="topic-3.1.2.6.1-3"></a>

###### Primary, key secondary, and key exploratory assessments

> “The primary assessment for the study was to evaluate the safety and tolerability of claseprubart.”
> “Key secondary efficacy assessments included change from baseline in the MG-ADL Scale Score, the Quantitative Myasthenia Gravis (QMG) Scale score, and the Myasthenia Gravis Composite (MGC) Scale Score.”
> “Key exploratory assessments included achievement of minimal symptom expression (MSE; MG-ADL score ≤1), Myasthenia Gravis Composite Score (MGC), and Myasthenia Gravis Quality of Life 15- item scale (MG-QoL15r).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.6.1-4"></a>

###### Registered secondary outcome measures: long-term safety, serum concentrations, CH50, and antidrug antibodies

> “Incidence of TEAEs and Treatment-Emergent SAEs Number of participants with TEAEs and treatment-emergent SAEs will be reported. Through OLE completion, an average of 117 weeks”
> “Serum Concentrations of Claseprubart Blood samples will be collected for measurement of serum concentrations of claseprubart at various timepoints both pre- and post-dose.”
> “Change from Baseline in Complement Total Blood Test (CH50) Blood samples will be collected to determine changes in CH50 at various timepoints.”
> “Incidence and Titer of Antidrug Antibody (ADAs) Against Claseprubart Blood samples will be collected to measure ADA against claseprubart at various timepoints.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-5"></a>

###### Efficacy measure: Myasthenia Gravis Activities of Daily Living scale

> “The MG-ADL score is an 8-item patient reported outcome (PRO) instrument. The MG-ADL targets symptoms of disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of the MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-6"></a>

###### Efficacy measure: Quantitative Myasthenia Gravis score

> “The QMG is a clinician-reported assessment to evaluate muscle strength. The QMG consists of 13 items that measure endurance or fatiguability, with each item having a possible score that ranges from 0 - 3. The total possible QMG scores range from 0 - 39, with a higher score indicating greater disease burden.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-7"></a>

###### Efficacy measure: Myasthenia Gravis Composite scale

> “The MGC is a validated assessment tool for measuring clinical status of participants with MG. The range of total MGC score is 0 to 50, with higher scores indicating more severe disease. A clinically meaningful improvement is reflected by a 3-point improvement in MGC score. The MGC assesses 10 important functional areas most frequently affected by MG and the scales are weighted for clinical significance that incorporates patient-reported outcomes.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-8"></a>

###### Efficacy measure: minimal symptom expression on MG-ADL and QMG

> “Here, we evaluated whether claseprubart use resulted in reaching minimal symptom expression (MSE), a measure of disease remission in gMG.”
> “MG-ADL-MSE was defined as achieving an MG-ADL score of 0 or 1.”
> “QMG-MSE was defined as achieving a QMG score of ≤3.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.6.1-9"></a>

###### Efficacy measure: revised 15-item Myasthenia Gravis Quality of Life scale

> “MG-QOL-15r, Myasthenia Gravis quality of life 15 revised.”
> “Secondary / Exploratory: Efficacy (MG-ADL, QMG MSE, MGC, MG-QoL-15r)”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned number of participants

> “Design: ~60 male and female subjects randomized to receive either claseprubart or placebo for 13 weeks”
> “Trial enrollment exceeded target, with 65 participants enrolled”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.7.1-2"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 65”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants randomized and treated by arm

> “Sixty-five patients with AChR Ab+ gMG were randomized and received 300mg SC claseprubart (n=21), 600mg SC claseprubart (n=22), or placebo (n=22).”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.7.1-4"></a>

###### Participants analyzed for MG-ADL minimal symptom expression at week 13

| Arm | Participants achieving MG-ADL MSE / analyzed |
| --- | --- |
| Placebo | “3/22” |
| Claseprubart 300 mg Q2W | “7/19” |
| Claseprubart 600 mg Q2W | “6/22” |

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.7.1-5"></a>

###### Participants in the pooled claseprubart group of the randomized period

> “Includes 21 patients who received claseprubart 300mg Q2W and 22 patients who received 600mg Q2W.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Mixed model for repeated measures for MG-ADL, QMG, and MGC

> “The change from baseline in MG-ADL was analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included.”
> “The change from baseline in MGC and MGC Summed Muscle Score were separately analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included.”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.7.2-2"></a>

###### Logistic regression for minimal symptom expression and general linear model for MG-QoL-15r

> “The proportion of participants who achieve MSE was analyzed using a logistic regression with terms for treatment group, stratification factors, and baseline MG-ADL included.”
> “The change from baseline in MG-QoL 15r was analyzed using a general linear model with treatment group, stratification factors, and baseline measure included.”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.7.2-3"></a>

###### One-sided and two-sided significance thresholds

> “One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.”
> “Two-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.05 considered nominally statistically significant.”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.7.2-4"></a>

###### Adjusted logistic regression for MG-ADL and QMG minimal symptom expression

> “Adjusted analysis uses a logistic regression model with terms for treatment group, baseline and stratification factors.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.7.2-5"></a>

###### Dual MG-ADL and QMG responder definition and endpoints

> “A responder was defined as achieving an improvement in MG‐ADL ≥ 3 and QMG ≥ 4. Endpoints include proportion of dual MG‐ADL and QMG responders at Week 13, time to response, and proportion of responders sustaining response for at least 6 weeks.”

Source: [Dimachkie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310587/)

<a id="topic-3.1.2.7.2-6"></a>

###### Pooled analysis of the two dose groups in the open-label extension

> “Since benefit/risk of 300mg and 600mg were similar in the RCT portion of the study, safety and efficacy data in the OLE are presented as pooled analyses.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Completion of the randomized controlled period and discontinuations by arm

| Measure | Placebo (n=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| Study discontinuations, n (%) | “1 (4.5)” | “1 (4.8)” | “0 (0)” |
| Due to AE, n (%) | “0 (0)” | “0 (0)” | “0 (0)” |

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.1-2"></a>

###### Sixty-three of 65 participants completed 13 weeks

> “Sixty-three of 65 patients completed the 13-week randomized controlled portion of the study. No patients discontinued due to adverse events (AEs) (Table 1).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.1-3"></a>

###### Discontinuations in the placebo and 300 mg arms

> “One placebo and one 300mg claseprubart patient discontinued, neither due to an adverse event.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.8.1-4"></a>

###### Entry into the open-label extension and duration of dosing

> “Sixty-three patients completed the 13-week RCT and 60 enrolled in the OLE (Table 1). The median time between first and last/latest dose in the OLE is 50 weeks.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Demographic and disease characteristics by arm

| Characteristic | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21) | Claseprubart 600 mg Q2W (N=22) |
| --- | --- | --- | --- |
| Age, mean (SD), years | “52.2 (16.5)” | “57.1 (13.7)” | “55.3 (12.0)” |
| Male, n (%) | “13 (59%)” | “14 (67%)” | “10 (45%)” |
| Weight, mean (SD), pounds | “195.0 (48.0)” | “192.5 (35.5)” | “179.0 (35.4)” |
| Duration of disease, median (range), years | “7.7 (0.4 – 21.2)” | “3.0 (0.5 – 22.1)” | “7.6 (1.0 – 37.3)” |
| MG-ADL score at baseline, mean (SD) | “8.5 (2.9)” | “8.2 (2.2)” | “8.4 (2.6)” |
| QMG score at baseline, mean (SD) | “14.2 (5.8)” | “12.2 (2.7)” | “12.2 (3.6)” |
| MG Composite score at baseline, mean (SD) | “15.0 (7.8)” | “16.3 (4.5)” | “16.0 (5.3)” |
| MG-QoL-15r score at baseline, mean (SD) | “14.3 (7.0)” | “15.4 (6.6)” | “14.9 (5.9)” |
| MGFA class II at screening, n (%) | “7 (32%)” | “11 (52%)” | “12 (55%)” |
| MGFA class III at screening, n (%) | “12 (55%)” | “10 (48%)” | “9 (41%)” |
| MGFA class IVa at screening, n (%) | “3 (14%)” | “0 (0%)” | “1 (5%)” |
| Prior thymectomy, n (%) | “8 (36%)” | “6 (29%)” | “7 (32%)” |
| Baseline corticosteroid use, n (%) | “19 (86%)” | “17 (81%)” | “20 (91%)” |
| One immunosuppressive therapy at baseline, n (%) | “11 (50%)” | “10 (48%)” | “12 (55%)” |
| More than one immunosuppressive therapy at baseline, n (%) | “11 (50%)” | “11 (52%)” | “10 (45%)” |
| FcRn use in prior 24 months, n (%) | “0 (0%)” | “1 (5%)” | “0 (0%)” |
| Prior complement use, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.8.2-2"></a>

###### Balance across arms

> “Participant baseline characteristics were generally well balanced across arms”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.8.2-3"></a>

###### Overall sex, age, and disease duration

> “Approximately 57% of patients in the study were male with a mean age of 54.8 (standard deviation 14.1) years and a median disease duration of 5.6 years.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Week 13 efficacy summary by arm with placebo-adjusted differences

| Measure at week 13 | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21), absolute | Claseprubart 300 mg Q2W, placebo-adjusted (one-sided P) | Claseprubart 600 mg Q2W (N=22), absolute | Claseprubart 600 mg Q2W, placebo-adjusted (one-sided P) |
| --- | --- | --- | --- | --- | --- |
| MG-ADL mean change from baseline | “-2.8” | “-4.6” | “-1.8 (P=0.0113)” | “-5.4” | “-2.6 (P=0.0006)” |
| QMG mean change from baseline | “-2.0” | “-4.4” | “-2.4 (P=0.0144)” | “-4.5” | “-2.5 (P=0.0111)” |
| MSE | “14%” | “37%” | “23% (P=0.0550)” | “27%” | “13% (P=0.1031)” |
| MGC mean change from baseline | “-3.1” | “-8.7” | “-5.6 (P=0.0008)” | “-8.6” | “-5.5 (P=0.0008)” |

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.3-2"></a>

###### MG-ADL change from baseline at week 13 by arm

> “Claseprubart dosed at 300mg S.C. Q2W achieved a statistically significant and clinically meaningful mean improvement from baseline of 4.6 points in MG-ADL score at Week 13 (placebo-adjusted improvement: 1.8 points; P=0.0113).”
> “Claseprubart dosed at 600mg S.C. Q2W achieved a statistically significant and clinically meaningful mean improvement from baseline of 5.4 points in MG-ADL score at Week 13 (placebo-adjusted improvement: 2.6 points; P=0.0006).”
> “As expected, there was no statistically significant difference between the claseprubart 300mg and 600mg arms in MG-ADL score at any time point.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.3-3"></a>

###### QMG change from baseline at week 13 by arm

> “Claseprubart dosed at 300mg S.C. Q2W achieved a statistically significant and clinically meaningful mean improvement from baseline of 4.4 points in QMG score at Week 13 (placebo-adjusted improvement: 2.4; P=0.0144).”
> “Claseprubart dosed at 600mg S.C. Q2W achieved a statistically significant and clinically meaningful mean improvement from baseline of 4.5 points in QMG score at Week 13 (placebo-adjusted improvement: 2.5; P=0.0111).”
> “As expected, there was no statistically significant difference between the claseprubart 300mg and 600mg arms in QMG score at any time point.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.3-4"></a>

###### Two-sided P values for MG-ADL and QMG at week 13

| Measure | Claseprubart 300 mg Q2W vs placebo, two-sided P | Claseprubart 600 mg Q2W vs placebo, two-sided P |
| --- | --- | --- |
| MG-ADL | “P=0.0227” | “P=0.0013” |
| QMG | “P=0.0288” | “P=0.0222” |

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.8.3-5"></a>

###### Week 1 onset of MG-ADL and QMG improvement

> “Significant improvement from baseline in MG-ADL was observed as early as Week 1 in 300mg (p=0.0906 vs. placebo) and 600mg (p=0.0211) groups compared to placebo (one-sided p-values, p<0.1 considered nominally significant).”
> “Claseprubart produced rapid improvement as early as Week 1 (300mg [p=0.0042 vs. placebo]; 600mg [p=0.0418]) compared to placebo.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-6"></a>

###### Improvement of 5 points or more on MG-ADL and QMG at week 13

> “Greater than 60% of patients achieved ≥5 point improvements in MG-ADL in both claseprubart dose groups at Week 13 (Figure 3B).”
> “At least 60% of patients achieved ≥5 point improvements in QMG in both claseprubart dose groups at Week 13 (Figure 3D).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-7"></a>

###### Dual MG-ADL and QMG responders at week 13

> “Results: 63% of claseprubart patients had dual response improvement in MG‐ADL ≥ 3 and QMG ≥ 4, versus 14% for placebo (OR 29.00; p = 0.0006). Dual responders were seen as early as Week 1. The median time to response was Week 3. All claseprubart patients with dual response at Week 13 had maintained response for at least 6 weeks.”

Source: [Dimachkie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310587/)

<a id="topic-3.1.2.8.3-8"></a>

###### MG-ADL minimal symptom expression at week 13

> “At Week 13, significantly more patients from the 300mg claseprubart arm (37% [7/19], adjusted odds ratio (OR) 3.81, p=0.0550 vs. placebo) achieved MG-ADL-MSE compared to 14% (3/22) of placebo-treated patients (Figure 4A).”
> “Achievement of MG-ADL-MSE was rapid with 300mg claseprubart, beginning at Week 5 (OR 4.60, p=0.0358 vs. placebo).”
> “Median time to achieve MG-ADL-MSE was 3 weeks with 300mg claseprubart.”
> “Of the 300mg claseprubart-treated patients who achieved MG-ADL-MSE at Week 13, all demonstrated MSE for at least 6 consecutive weeks.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.8.3-9"></a>

###### QMG minimal symptom expression at week 13

> “QMG-MSE was achieved by significantly more 300mg claseprubart-treated patients at Week 13 (32% [6/19], OR 5.84, p=0.0387 vs. placebo) compared to placebo-treated patients (9% [2/22]) (Figure 4B).”
> “Median time to achieve QMG-MSE was 3 weeks with 300mg claseprubart.”
> “Of the 300mg claseprubart-treated patients who achieved QMG-MSE at Week 13, five of six patients demonstrated MSE for at least 6 consecutive weeks.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.8.3-10"></a>

###### MG-ADL minimal symptom expression at week 13 in both dose groups

> “At Week 13, significantly more claseprubart-treated patients achieved MSE in the 300mg (36.8%; p=0.0550) compared to placebo (13.6%) (one-sided p-values, p<0.1 considered nominally significant).”
> “Twenty- seven percent of claseprubart 600mg patients achieved MSE at Week 13 though not significantly different from placebo.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-11"></a>

###### MGC placebo-adjusted change with 80% confidence intervals

> “MGC scores were significantly improved from baseline to Week 13 in the 300mg (–4.1 placebo-adjusted [80% CI –6.0, –2.3]; p=0.0023 vs. placebo) and 600mg (–4.3 placebo-adjusted [80% CI –6.1, –2.5]; p=0.0016).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-12"></a>

###### Post hoc subgroup with baseline QMG score of 10 or higher

> “MG-ADL improvement in the 300mg claseprubart arm (dose used in the upcoming Phase 3 study) was also assessed in patients with QMG score ≥10 at baseline. In this sub-group, the claseprubart 300mg arm (n=18) demonstrated greater improvement in MG-ADL score (–3.0 placebo-adjusted; p=0.0006) compared to the placebo arm (n=16) at Week 13.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-13"></a>

###### Open-label extension: sustained response through 65 weeks of treatment

> “Claseprubart patients who continued with Q2W claseprubart in the OLE demonstrated sustained improvement in MG-ADL (Figure 3A), QMG (Figure 3B), and MGC (Figure 3C) at OLE Week 52 compared to the end of RCT (65 total weeks on treatment).”
> “Rapid improvements in MG-ADL (Figure 3A), QMG (Figure 3B), MGC (Figure 3C) were observed as early as OLE Week 2 after switching from placebo to Q2W claseprubart.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.8.3-14"></a>

###### Open-label extension: change from extension baseline to week 52 in the MG-ADL, QMG, and MGC panels

> “Mean change from OLE baseline at Week 52: –0.8 for pooled claseprubart arm –3.3 for placebo to claseprubart arm”
> “Mean change from OLE baseline at Week 52: –0.1 for pooled claseprubart arm –4.5 for placebo to claseprubart arm”
> “Mean change from OLE baseline at Week 52: –1.4 for pooled claseprubart arm –5.5 for placebo to claseprubart arm”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.8.3-15"></a>

###### Open-label extension: week 4 response after switching from placebo

> “A robust MG-ADL decline at week 4 in the open-label extension (OLE) of -2.5 points and QMG score reduction of -3.2 points for patients on placebo during the RCT who received only two doses of claseprubart 600mg/4mL Q2W without a loading dose and achieved a PK level far below the steady state of 300mg/2mL Q2W, supporting potential for Q4W dosing of 300mg/2mL”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="topic-3.1.2.8.3-16"></a>

###### Open-label extension: serum concentration after two 600 mg doses

> “PK of ~65 µg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 µg/mL”
> “Robust reductions in MG-ADL and QMG are achieved by week 4, after just two 600mg/4mL doses and remain stable in subsequent weeks”

Source: [Dianthus Therapeutics presentation (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525262188/dnth-ex99_1.htm)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### MG-QoL-15r change from baseline at week 13 by arm with placebo-adjusted differences

| Measure at week 13 | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21), absolute | Claseprubart 300 mg Q2W, placebo-adjusted (one-sided P) | Claseprubart 600 mg Q2W (N=22), absolute | Claseprubart 600 mg Q2W, placebo-adjusted (one-sided P) |
| --- | --- | --- | --- | --- | --- |
| MG-QoL-15r mean change from baseline | “-3.9” | “-6.1” | “-2.2 (P=0.0414)” | “-5.4” | “-1.5 (P=0.1122)” |

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.4-2"></a>

###### MG-QoL-15r change from baseline with standard deviations

> “Patient-reported quality of life (MG-QoL15r) was also significantly improved from baseline to Week 13 with 300mg claseprubart (–5.0 [SD 3.96]; p=0.0414) compared to placebo (–2.7 [SD 4.48]). The claseprubart 600mg group also showed improved MG-QoL15r scores at Week 13 (–4.2 [SD 3.85]; p=0.1122), which was not significantly different from placebo.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Safety and tolerability during the 13-week randomized controlled period

| Event, n (%) | Placebo (n=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| Any treatment-related AEs | “13 (59.1)” | “15 (71.4)” | “21 (95.5)” |
| Clinical AEs | “11 (50.0%)” | “13 (61.9%)” | “15 (68.2%)” |
| Treatment-related serious AEs | “1 (4.5%)” | “0 (0%)” | “0 (0%)” |
| Infections | “10 (45.5%)” | “5 (23.8%)” | “6 (27.3%)” |
| Treatment-related serious infections | “1 (4.5%)” | “0 (0%)” | “0 (0%)” |
| Injection site reactions | “0 (0%)” | “2 (9.5%)” | “2 (9.1%)” |
| Newly positive for ANA | “0 (0%)” | “1 (5.9%)” | “8 (36.4%)” |
| Rashes | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Arthralgia | “1 (4.5%)” | “1 (4.8%)” | “0 (0%)” |

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.5-2"></a>

###### Table footnotes: clinical adverse events, injection site reactions, and antinuclear antibodies

> “Excludes events in the investigations System Organ Class (MedDRA).”
> “All injection site reactions were mild to moderate.”
> “Represents participants who were ANA negative at baseline and tested positive at ≥1:320 at any point during RCT (percentages calculated from n=17 for 300mg arm and n=22 for 600mg arm).”
> “At end of RCT (Week 13), 2 of the 8 patients in 600mg arm tested negative for ANA, 2 of the 8 patients in 600mg arm remained positive but at <1:320.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.5-3"></a>

###### Severity of treatment-related adverse events, serious adverse events, infections, and autoimmune activation

> “Claseprubart was generally well tolerated with a safety profile similar to the placebo group (Table 2).”
> “All treatment-related AEs with both doses of claseprubart were mild or moderate in severity, and no patients receiving claseprubart developed a serious AE related to treatment.”
> “No significant safety findings were observed regarding infections or autoimmune activation with either claseprubart dose group.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.5-4"></a>

###### Discontinuation due to related adverse events in the randomized controlled period

| Event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| RCT discontinuation due to related AE | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.8.5-5"></a>

###### Most common adverse events in more than 5% of participants in any arm

| Adverse event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| Nasopharyngitis | “1 (4.5)” | “3 (14.3%)” | “3 (13.6)” |
| Lipase increased | “0 (0%)” | “3 (14.3%)” | “2 (9.1%)” |
| Upper respiratory tract infection | “3 (13.6%)” | “0 (0%)” | “1 (4.5%)” |
| Sinusitis | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
| Headache | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
| Diarrhea | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.8.5-6"></a>

###### Myasthenia gravis exacerbations in the randomized controlled period

| Event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| Myasthenia gravis exacerbations | “2 (9.1%)” | “2 (9.5%)” | “2 (9.1%)” |

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.8.5-7"></a>

###### Definition and management of myasthenia gravis exacerbations

> “Defined as worsening of disease regardless of receiving rescue treatment. No patients required respiratory intervention and one patient in each arm received rescue treatment for the exacerbation.”
> “One patient had MG worsening attributed to missed Mestinon doses on the first day of claseprubart dosing (Day 1).”
> “All treatment-related adverse events in both claseprubart arms were mild or moderate in severity.”

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.8.5-8"></a>

###### Infections, autoimmune symptoms, and injection site reactions reported with top-line results

> “No infection signal was observed, including no related serious bacterial infections in the treatment arms; the only related serious adverse event (SAE) of infection occurred in the placebo arm.”
> “There were no symptoms indicative of autoimmune activation.”
> “Injection site reactions (ISRs) were infrequent and generally mild, and there were no claseprubart discontinuations from RCT due to related AEs.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.5-9"></a>

###### Injection site reaction severity in the top-line abstract

> “Injection site reactions were infrequent, mild to moderate, with the majority mild.”

Source: [Peric et al. (2026b)](https://www.aan.com/msa/Public/Events/AbstractDetails/61545)

<a id="topic-3.1.2.8.5-10"></a>

###### Open-label extension: adverse events through 52 weeks compared with the randomized controlled period

| Adverse event, n (%) | Randomized period: placebo (n=22) | Randomized period: pooled claseprubart (n=43) | Open-label extension: all claseprubart (n=60) |
| --- | --- | --- | --- |
| Clinical AEs | “11 (50.0)” | “28 (65.1)” | “45 (75.0)” |
| Related serious AEs | “1 (4.5)” | “0 (0.0)” | “1 (1.7)” |
| Discontinuation due to related AE | “0 (0)” | “0 (0)” | “1 (1.7)” |
| Infections | “10 (45.5)” | “11 (25.6)” | “28 (46.7)” |
| Related serious infections | “1 (4.5)” | “0 (0)” | “1 (1.7)” |
| Injection site reaction | “0 (0)” | “4 (9.3)” | “1 (1.7)” |
| Arthralgia | “1 (4.5)” | “1 (1.7)” | “4 (6.7)” |
| Myasthenia gravis exacerbation | “2 (9.1)” | “4 (9.3)” | “7 (11.7)” |

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.8.5-11"></a>

###### Open-label extension: table footnotes on the serious infection, discontinuation, and exacerbations

> “Patient with influenza who recovered and restarted claseprubart treatment (not considered related by sponsor).”
> “Patient with arthritis.”
> “Defined as worsening of disease regardless of receiving rescue treatment. No patients required respiratory intervention. During the RCT period two claseprubart patients received rescue treatment for the exacerbation and one patient had MG worsening attributed to missed pyridostigmine doses on the first day of claseprubart dosing (Day 1). During the OLE six patients received rescue therapy for the exacerbation.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.8.5-12"></a>

###### Open-label extension: consistency with the randomized period, meningococcal infections, and one death

> “Safety and tolerability of claseprubart in the OLE was consistent with the RCT, including no meningococcal infections.”
> “There was one death from a cardiovascular event deemed unrelated to claseprubart during the safety follow-up period in a 71-year-old male subject with a history of preexisting diabetes mellitus, hypertension, smoking, dyslipidemia and chronic obstructive pulmonary disease.”
> “Long-term treatment with claseprubart in the open-label extension demonstrated a sustained efficacy profile over 65 weeks with no new safety findings.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

MaGic is a phase 2 trial in which 65 participants with acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1:1 to claseprubart 300 mg every 2 weeks (21 participants), claseprubart 600 mg every 2 weeks (22 participants), or placebo (22 participants) for 13 weeks. The primary endpoint was safety and tolerability, measured as the incidence of treatment-emergent adverse events and serious adverse events to week 13; MG-ADL, QMG, and MGC were secondary endpoints, and minimal symptom expression and MG-QoL-15r were exploratory. Efficacy comparisons with placebo used one-sided P values, with values below 0.1 considered nominally significant, the MG-ADL result in participants with a baseline QMG score of 10 or higher came from a post hoc analysis of 18 and 16 participants, and the open-label extension pooled both dose groups without a placebo comparison after week 13. The results reported through November 2026 appear in company press releases and presentations and in congress posters and abstracts, and no peer-reviewed full article reporting the trial was identified.

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159); [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm); [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm); [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented); [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e); [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.9-2"></a>

###### Nominal significance threshold of one-sided P below 0.1

> “p ‐values are one‐sided, with nominal significance assessed at an alpha of 0.1.”

Source: [Dimachkie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310587/)

<a id="topic-3.1.2.9-3"></a>

###### Post hoc analysis of the subgroup with baseline QMG score of 10 or higher

> “This post hoc analysis is driving our decision to add a QMG inclusion criteria and a 300mg/2mL S.C. Q4W arm, in addition to a Q2W arm, in our Phase 3 MG study,”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="topic-3.1.2.9-4"></a>

###### No QMG inclusion criterion in the phase 2 trial

> “Ph. 2 study did not include QMG inclusion criteria, similar to ravulizumab Ph. 3; post-hoc analysis of MaGic data demonstrates potentially best-in-class MG-ADL improvement in patients with QMG ≥10”

Source: [Dianthus Therapeutics presentation (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525262188/dnth-ex99_1.htm)

<a id="topic-3.1.2.9-5"></a>

###### No head-to-head comparison with other therapies

> “Safety and efficacy for claseprubart has not been evaluated in head-to-head comparative clinical studies.”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="heading-3.1.3"></a>

#### 3.1.3 DNTH103-AU-001

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Primary objectives in the Part A and Part B registry record

> “To evaluate the safety and tolerability of DNTH103 when administered IV or SC as a single dose in healthy adult volunteers.”
> “To evaluate the safety and tolerability of DNTH103 when administered IV or SC as multiple doses in healthy adult volunteers.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.1-2"></a>

###### Secondary objectives in the Part A and Part B registry record

> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV or SC as a single dose in healthy adult volunteers.”
> “To evaluate the immunogenicity of DNTH103 when administered IV or SC as a single dose in healthy adult volunteers.”
> “To evaluate the effect of DNTH103 on the classical complement pathway when administered IV or SC as a single dose in healthy adult volunteers.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.1-3"></a>

###### Part C objectives: pharmacokinetics after human normal immunoglobulin G

> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV following administration of IgG, as a single dose in healthy adult volunteers.”
> “To evaluate the PK of DNTH103 when administered SC following administration of IgG, as a single dose in healthy adult volunteers.”
> “To evaluate the immunogenicity of DNTH103 when administered IV following administration of IgG as a single dose in healthy adult volunteers.”
> “To evaluate the effect of DNTH103 on the classical complement pathway when administered IV following administration of IgG as a single dose in healthy adult volunteers.”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.3.1-4"></a>

###### Objectives stated by the company at study start and at top-line results

> “Data from this Phase 1 study will provide important information about the safety, tolerability, pharmacokinetics and pharmacodynamics of DNTH103 in healthy adult volunteers across single and multiple ascending dose cohorts”

Source: [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)

> “The Phase 1 healthy volunteer study was designed to validate the extended half-life, potent classical pathway inhibition, and potentially differentiated safety profile of DNTH103.”

Source: [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Registration, recruitment dates, and status of Parts A and B

> “Date registered 23/09/2022”
> “Type of registration Prospectively registered”
> “Recruitment status Completed”
> “Date of first participant enrolment Anticipated 17/11/2022 Actual 19/11/2022”
> “Date of last participant enrolment Anticipated 31/03/2024 Actual 18/03/2024”
> “Date of last data collection Anticipated 15/09/2024 Actual 6/01/2025”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.2-2"></a>

###### Study location, sponsors, and ethics committee

> “Recruitment outside Australia Country [1] New Zealand State/province [1] Christchurch”
> “Primary sponsor type Commercial sector/Industry Name Dianthus Therapeutics, Inc.”
> “Secondary sponsor category [1] Commercial sector/Industry Name [1] Avance Clinical Pty Ltd”
> “Ethics committee name [1] Southern Health and Disability Ethics Committee”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.2-3"></a>

###### Registration, recruitment dates, and status of Part C

> “Date registered 27/03/2024”
> “Type of registration Retrospectively registered”
> “This record is a sub study of ACTRN12622001265763”
> “Date of first participant enrolment Anticipated Actual 12/12/2023”
> “Date of last participant enrolment Anticipated Actual 18/03/2024”
> “Date of last data collection Anticipated Actual 6/01/2025”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.3.2-4"></a>

###### First participant dosed, November 2022

> “November 30, 2022 – Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced that the first healthy volunteers have been dosed in a Phase 1 clinical trial of its lead monoclonal antibody, DNTH103.”

Source: [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)

<a id="topic-3.1.3.2-5"></a>

###### Trial initiation and top-line data dates reported by the company

> “Ph. 1 HV trial initiated in November 2022”
> “Top-line Ph. 1 data demonstrated potent, long-acting classical pathway inhibition in August 2023”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.3.2-6"></a>

###### Country of the trial

> “We conducted our Phase 1 clinical trial for claseprubart in New Zealand”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Single ascending dose and multiple ascending dose parts

> “The study will be conducted in two parts: Part A, the single ascending dose (SAD) portion, and Part B, the multiple ascending dose (MAD) portion. Participants in Part A and Part B will be distinct.”
> “Each cohort will enroll 8 participants with 6 participants randomised to receive DNTH103 and 2 participants randomised to receive placebo. The first two subjects dosed in each cohort will be considered sentinel subjects, one each receiving active study drug and placebo.”
> “The time separation between Part A and Part B is not fixed. Part B will not commence until safety at the higher dose in Part A is determined through an SRC review.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.3-2"></a>

###### Randomization and blinding of Parts A and B

> “Allocation to intervention Randomised controlled trial”
> “The allocation to DNTH103 or placebo will be performed using a block randomisation algorithm and will be documented in the study randomisation schedule.”
> “This study is a double-blind study. Those blinded to study drug assignment include the Investigator, site staff (other than pharmacists), Sponsor, the PI, clinical study personnel participating in participants’ care or clinical evaluations, and the study participants.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.3-3"></a>

###### Part C: open-label, uncontrolled single cohort

> “Part C will be open label and will not be placebo controlled.”
> “No sentinel dosing is required.”
> “Part C will be initiated after dosing and SRC review is completed for Part A cohort SAD IV4.”
> “Allocation to intervention Non-randomised trial”
> “Masking / blinding Open (masking not used)”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.3.3-4"></a>

###### First-in-human design described by the company

> “We evaluated DNTH103 in a first-in-human Phase 1 single ascending dose”
> “clinical trial in New Zealand to explore the safety, tolerability, PK, and pharmacodynamics”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Key inclusion criteria

> “Adult males and females, 18 to 65 years of age (inclusive) at Screening.”
> “Body mass index less than or equal to 32 kg/m2, with a body weight (to 1 decimal place) greater than or equal to 45 kg and less than or equal to 100 kg at Screening.”
> “Medically healthy without clinically significant abnormalities (in the opinion of the Investigator) at the Screening visit and after check-in on Day -1, prior to dose administration on Day 1”
> “Previously immunized against encapsulated bacterial pathogens as per country-specific guidelines (Neisseria meningitis, Haemophilus influenza, and Streptococcus pneumonia within past 5 years) or willing and able to be vaccinated during the Screening Period and at least 14 days prior to study drug administration on Day 1.”
> “Healthy volunteers Yes”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.4-2"></a>

###### Key exclusion criteria

> “History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within 3 months prior to screening determined by the PI to be clinically significant.”
> “History of autoimmune disease or positive autoantibody test result at Screening.”
> “Estimated creatinine clearance (CrCl) < 60 mL/min during Screening or at check-in day (Day -1) using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.”
> “Administration of any live, attenuated vaccines within 30 days and all other vaccinations within 14 days prior to study drug administration.”
> “Females who are breastfeeding or planning to breast feed at any time during the study.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.4-3"></a>

###### Part C eligibility

> “Adult males and females, 18 to 65 years of age (inclusive) at Screening.”
> “History of autoimmune disease or positive autoantibody test result at Screening.”
> “Healthy volunteers Yes”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Planned Part A single-dose cohorts

> “Single dose DNTH103 or placebo administered on Day 1 (IV or SC) as follows:”
> “SAD IV1, 1 mg/kg”
> “SAD IV2, 3 mg/kg”
> “SAD IV3, 10 mg/kg”
> “SAD IV4, 30 mg/kg”
> “SAD IV5, 60 mg/kg”
> “SAD SC1, 300 mg”
> “SAD SC2, 600 mg”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.5-2"></a>

###### Planned Part B multiple-dose cohorts

> “DNTH103 or placebo is scheduled to be administered at 2-week intervals on Day 1, Day 15 and Day 29 (total of three doses) as follows:”
> “MAD SC1, 300 mg”
> “MAD SC2, 600 mg”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.5-3"></a>

###### Placebo comparator

> “Placebo (matching IV infusion or SC injection) and a sterile saline for IV injection, or excipient alone for SC injection.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.5-4"></a>

###### Dose cohorts reported as dosed

> “We reported data from 60 healthy volunteers that have been dosed across eight cohorts, including six SAD cohorts: 1mg/kg intravenous”
> “10mg/kg I.V., 30mg/kg I.V., 50mg/kg I.V., 300mg S.C. and 600mg S.C.; and two MAD cohorts: 300mg S.C. and 600mg. S.C.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-3.1.3.5-5"></a>

###### Part C: intravenous immunoglobulin before a single dose of DNTH103

> “Single dose DNTH103, administered on Day 1 after administration of Privigen NZ solution for IV infusion on Days -8 and -7”
> “IV7, 0.5 g/kg of body weight per day for 2 consecutive days (total dose: 1 g/kg)”
> “Investigational Product: DNTH103 IV infusion, 1 week after Privigen NZ solution:”
> “IV7, 10 mg/kg”
> “Investigational Product: DNTH103 SC injection, 1 week after Privigen NZ solution:”
> “IV7, 600 mg”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary safety endpoints and adverse event grading

> “Incidence, severity and relationship of treatment-emergent adverse events (TEAE)”
> “Incidence, severity and relationship of adverse events of special interest”
> “Incidence, severity and relationship of treatment-emergent adverse events (TEAE) and AEs of special interest graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) (Version 5).”
> “Final Safety Follow Up (determined when the participant’s CH50 level has met normalization criteria).”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.6.1-2"></a>

###### Safety as the purpose of a first-in-human study

> “This is a first in human study for DNTH103.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

> “Claseprubart Phase 1 healthy volunteer study was designed to validate extended half-life, potency and safety”
> “Safety, PK, and PD measured by percent classical pathway inhibition quantified in each cohort”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="topic-3.1.3.6.1-3"></a>

###### Infection risk with complement inhibition

> “by leaving the lectin and alternative pathways intact, the risk of infection from encapsulated bacteria is lower for DNTH103 versus commonly used C5 and C3 inhibitors.”

Source: [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)

<a id="topic-3.1.3.6.1-4"></a>

###### Secondary pharmacokinetic, pharmacodynamic, and immunogenicity endpoints

> “Maximum concentration (Cmax)”
> “Terminal elimination half-life (t½)”
> “Absolute bioavailability (Fabs)”
> “Complement system classical pathway (CP) inhibition measures in serum ex vivo by the WIESLAB® assay”
> “CH50 (complement haemolysis 50%) in serum ex vivo”
> “Incidence of anti-drug antibody (ADA) to DNTH103”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.6.1-5"></a>

###### Part C: pharmacokinetics as the primary endpoint

> “Type of endpoint/s Pharmacokinetics”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment and sample size basis in the Part A and Part B registry record

> “Part A: Up to approximately 72 participants are planned to be enrolled as follows:”
> “56 healthy volunteers will be enrolled into seven SAD cohorts, five cohorts receiving study drug as an intravenous (IV) infusion and two receiving study drug as a subcutaneous (SC) injection.”
> “Part B: Up to approximately 24 participants are planned to be enrolled as follows:”
> “As such, no formal sample size calculations have been performed. The number of participants in each treatment arm is considered sufficient to achieve the objectives of the study.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.3.7.1-2"></a>

###### Final accrual in the registry records, last updated June 2025

> “Date last updated 8/06/2025”
> “Sample size Target 96 Accrual to date Final 68”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

> “Up to a maximum of 8 participants will be enrolled in a single cohort (IV7)”
> “Sample size Target 8 Accrual to date Final 9”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.3.7.1-3"></a>

###### Participants in the top-line analysis, September 2023

> “Top-line data across seven single and multiple ascending dose cohorts with 52 healthy volunteers confirmed its approximately 60-day half-life and highly potent classical pathway inhibition”

Source: [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)

<a id="topic-3.1.3.7.1-4"></a>

###### Participants by part reported in January 2024

> “44 HVs enrolled into six cohorts: Placebo (N= up to 2) Treated (N= up to 6)”
> “16 HVs enrolled into two cohorts: Placebo (N= up to 2) Treated (N= up to 6)”
> “Data comprised of 60 HVs from 8 cohorts”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.3.7.1-5"></a>

###### Participants reported in the annual report filed March 2025

> “Data from DNTH103’s Phase 1 clinical trial in 60 healthy volunteers across eight dose cohorts validates the extended half-life and potent classical pathway inhibition and supports a potentially differentiated safety profile of DNTH103.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Safety, pharmacokinetic, pharmacodynamic, and immunogenicity populations

> “The safety population will consist of all randomised participants who received any amount of study drug. Participants will be analysed according to actual treatment received.”
> “The PK population will include all randomised participants who received treatment where there is at least one post-dose measurement of serum PK concentration data.”
> “The PD population will include all randomised participants who receive any amount of study treatment, who have at least 1 evaluable post-dose PD parameter and will be analysed based on the actual treatment received.”
> “The immunogenicity population will include all randomised participants who receive any amount of study treatment, who have at least 1 evaluable post-dose immunogenicity parameter, and will be analysed based on the actual treatment received.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Participants who completed dosing, as of December 2023

> “In completed cohorts, 60 healthy volunteers completed dosing as of December 2023”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

> “60 healthy volunteers completed dosing as of December 2023 across these eight cohorts”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="topic-3.1.3.8.1-2"></a>

###### Completion of treatment after injection site reactions

> “No intervention was required and both participants completed treatment”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Pharmacokinetic results: half-life and dose proportionality

> “DNTH103 demonstrated a ~60-day half-life and IC90 of 87 µg/mL”
> “I.V. SAD: Linear PK with Exposure Proportional Across Doses”
> “S.C. MAD: Strong Accumulation with Q2W Dosing”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

> “Additionally, based on data from this clinical trial, DNTH103 has a half-life of approximately 60 days.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-3.1.3.8.3-2"></a>

###### Pharmacodynamic results: classical pathway inhibition and simulated steady state

> “With these data, we conducted a PK simulation that demonstrates the steady state serum concentration of DNTH103, when dosed 300mg S.C. Q2W following an initial I.V. loading dose, exceeds the serum concentration required to surpass 90% classical pathway inhibition in a hemolytic assay”
> “estimated to be 87ug/mL”
> “We believe, based on published scientific literature related to other complement therapies, that the IC90 will be sufficient to achieve clinical activity in patients with gMG, CIDP, and MMN.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

> “Simulation using data from 60 healthy volunteers dosed across multiple cohorts demonstrates potent inhibition with infrequent S.C. dosing”
> “600mg S.C. Q2W dosing surpasses IC95, currently calculated at 149 µg/mL”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.3.8.3-3"></a>

###### Dose selection for later trials based on phase 1 data

> “Ph. 1 data in 2023 showed potency and long half-life, and DNTH103 was generally well tolerated, allowing for 300mg/2mL Q2W S.C. dosing”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

> “Phase 1 data estimated IC90 at ~87 µg/mL, leading to target dose of 300mg/2mL in Ph. 2 to achieve steady state >IC90”
> “Highest dose used in Phase 2 trial was single I.V. loading dose of 20mg/kg”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="topic-3.1.3.8.3-4"></a>

###### Part C pharmacokinetics after immunoglobulin G

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Overall tolerability, serious adverse events, and infections

> “The results also demonstrated DNTH103 was generally well tolerated with no serious adverse events or complement-related infections.”

Source: [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)

> “Claseprubart was generally well tolerated with no SAEs or complement-related infections.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-3.1.3.8.5-2"></a>

###### Adverse events reported across the eight cohorts

> “DNTH103 was generally well tolerated, with a favorable safety profile in Phase 1”
> “No standard safety lab findings (hematology, chemistry, coagulation LFTS and renal function)”
> “No serious adverse events”
> “No infection adverse event signal and no infections related to encapsulated bacteria”
> “Five participants experienced mild/moderate Treatment Related AEs”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.3.8.5-3"></a>

###### Injection site reactions, infusion events, and vomiting

> “Two participants (one in each 300mg and 600mg S.C. MAD cohorts) had a mild or moderate injection site reactions (ISRs)”
> “One participant experienced several non-specific AEs during infusion; infusion was paused for 8 minutes and restarted at the same rate without sequelae”
> “One participant in 600mg S.C. SAD reported vomiting on Day 1, which resolved on same day”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.3.8.5-4"></a>

###### Antinuclear antibody positivity in the 50 mg/kg intravenous cohort

> “Two participants in 50mg/kg SAD I.V.1 cohort became ANA”
> “positive at Day 57; both participants had no evidence of SLE and both tested negative for dsDNA”
> “One participant subsequently tested negative for ANA in a one-month safety follow-up post Day 57”
> “Other participant experienced inflammatory arthritis and tested negative on broader autoimmune panel”
> “Non-specific indicator of autoimmune disease present in up to 25% of healthy individuals”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.3.8.5-5"></a>

###### Part C safety

No evidence found.

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

DNTH103-AU-001 enrolled healthy adults aged 18 to 65 years and excluded people with a history of autoimmune disease, so its safety, pharmacokinetic, and pharmacodynamic findings come from a population without the diseases claseprubart is being developed to treat, and the company states that the same results may not be seen in patients in later trials. Each dose cohort was planned with 8 participants (6 receiving DNTH103 and 2 receiving placebo); the company reported 52 healthy volunteers in seven cohorts in its top-line announcement and 60 healthy volunteers in eight cohorts who completed dosing as of December 2023, while the registry records a final accrual of 68 for Parts A and B and 9 for the open-label, uncontrolled Part C. The ACTRN12622001265763 record lists recruitment in Christchurch, New Zealand, and neither registry record has uploaded results documents, so the available results come from company press releases, presentations, and annual reports, and no Part C result has been reported. The company states that FDA acceptance of data from trials conducted outside the United States is subject to conditions the FDA imposes.

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx); [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx); [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data); [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm); [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm); [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-3.1.3.9-2"></a>

###### Results limited to healthy volunteers and phase 1 data

> “We currently have only preclinical data and data from our Phase 1 clinical trial regarding properties of DNTH103 and the same results may not be seen in patients in our later stage trials.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-3.1.3.9-3"></a>

###### No results documents in the registry records

> “Documents added manually No documents have been uploaded by study researchers.”
> “Will the study consider sharing individual participant data? No”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

> “Documents added manually No documents have been uploaded by study researchers.”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.3.9-4"></a>

###### Trial conducted outside the United States

> “Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA.”
> “The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
